|
1
|
Faderl S, Talpaz M, Estrov Z, O'Brien S,
Kurzrock R and Kantarjian HM: The biology of chronic myeloid
leukemia. N Engl J Med. 341:164–172. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Branford S, Rudzki Z, Walsh S, Parkinson
I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, et
al: Detection of BCR-ABL mutations in patients with CML treated
with imatinib is virtually always accompanied by clinical
resistance, and mutations in the ATP phosphate-binding loop
(P-loop) are associated with a poor prognosis. Blood. 102:276–283.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nicolini FE, Corm S, Lê QH, Sorel N,
Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, et
al: Mutation status and clinical outcome of 89 imatinib
mesylate-resistant chronic myelogenous leukemia patients: A
retrospective analysis from the French intergroup of CML
(Fi(phi)-LMC GROUP). Leukemia. 20:1061–1066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arzoun H, Srinivasan M, Thangaraj SR,
Thomas SS and Mohammed L: The progression of chronic myeloid
leukemia to myeloid sarcoma: A systematic review. Cureus.
14:e210772022.PubMed/NCBI
|
|
5
|
Tsuchiya K, Tabe Y, Ai T, Ohkawa T, Usui
K, Yuri M, Misawa S, Morishita S, Takaku T, Kakimoto A, et al:
Eprobe mediated RT-qPCR for the detection of leukemia-associated
fusion genes. PLoS One. 13:e02024292018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah NP, Nicoll JM, Nagar B, Gorre ME,
Paquette RL, Kuriyan J and Sawyers CL: Multiple BCR-ABL kinase
domain mutations confer polyclonal resistance to the tyrosine
kinase inhibitor imatinib (STI571) in chronic phase and blast
crisis chronic myeloid leukemia. Cancer Cell. 2:117–125. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Bayati A, Al-Bayti A and Husain V: A
short review about chronic myeloid leukemia. J Life Bio Sci Res.
4:15–19. 2023. View Article : Google Scholar
|
|
8
|
Iqbal Z, Absar M, Akhtar T, Aleem A,
Jameel A, Basit S, Ullah A, Afzal S, Ramzan K, Rasool M, et al:
Integrated genomic analysis identifies ANKRD36 gene as a novel and
common biomarker of disease progression in chronic myeloid
leukemia. Biology (Basel). 10:11822021.PubMed/NCBI
|
|
9
|
Seman ZA, Ahid F, Kamaluddin NR, Sahid
ENM, Esa E, Said SSM, Azman N, Mat WKDW, Abdullah J, Ali NA, et al:
Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid
leukemia patients with tyrosine kinase inhibitors resistance: A
Malaysian cohort study. BMC Res Notes. 17:1112024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vinhas R, Lourenço A, Santos S, Lemos M,
Ribeiro P, de Sousa AB, Baptista PV and Fernandes AR: A novel
BCR-ABL1 mutation in a patient with Philadelphia
chromosome-positive B-cell acute lymphoblastic leukemia.
OncoTargets Ther. 11:8589–8598. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri
M, Misawa S, Horii T, Kawaguchi A, Ohsaka A and Kimura S: A new
highly sensitive real-time quantitative-PCR method for detection of
BCR-ABL1 to monitor minimal residual disease in chronic myeloid
leukemia after discontinuation of imatinib. PLoS One.
14:e02071702019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marin AM, Soares GS, Zanette DL and Aoki
MN: Molecular Biology for BCR-ABL1 quantification for
chronic myeloid leukemia monitorization and evaluation. Arch Cancer
Biol Ther. 2:40–42. 2021.PubMed/NCBI
|
|
13
|
Radich JP, Deininger M, Abboud CN, Altman
JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib
J, et al: Chronic myeloid leukemia, version 1.2019, NCCN clinical
practice guidelines in oncology. J Natl Compr Cancer Netw.
16:1108–1135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shah NP, Bhatia R, Altman JK, Amaya M,
Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, et
al: Chronic myeloid leukemia, version 2.2024, NCCN clinical
practice guidelines in oncology. J Natl Compr Cancer Netw.
22:43–69. 2024. View Article : Google Scholar
|
|
15
|
Branford S, Melo JV and Hughes TP:
Selecting optimal second-line tyrosine kinase inhibitor therapy for
chronic myeloid leukemia patients after imatinib failure: Does the
BCR-ABL mutation status really matter? Blood. 114:5426–5435. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahn JS, Kim YK, Lee SR, Yu L, Yang DH, Cho
SH, Shim HJ, Bae WK, Lee JJ, Chung IJ, et al: Coexisting with
clonal evolution and BCR-ABL mutant in CML patients treated with
second-generation tyrosine kinase inhibitors predict the
discrepancy of in vitro drug sensitivity. Cancer Res Treat.
42:37–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Srivastava S and Dutt S: Imatinib mesylate
resistance and mutations: An Indian experience. Indian J Med
Paediatr Oncol. 34:213–220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kaleem B, Shahab S and Shamsi TS: T315I-a
gatekeeper point mutation and its impact on the prognosis of
chronic myeloid leukemia. Adv Lab Med. 5:412–417. 2024.PubMed/NCBI
|
|
19
|
Soverini S, Colarossi S, Gnani A, Rosti G,
Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E,
Orlandi E, et al: Contribution of ABL kinase domain mutations to
imatinib resistance in different subsets of Philadelphia-positive
patients: By the GIMEMA working party on chronic myeloid leukemia.
Clin Cancer Res. 12:7374–7379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elsir Khair H, Ahmed Mohamed B, Yousef
Nour B and Ali Waggiallah H: Prevalence of BCR-ABL T315I mutation
in different chronic myeloid leukemia patients categories. Pak J
Biol Sci. 25:175–181. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Zhang Y, Zu Y, Li Z, Li M and Song
Y: Characteristics and clinical outcome of T315I mutation in
Philadelphia chromosome-positive acute lymphoblastic leukemia and
chronic myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 37:110–114.
2016.(In Chinese). PubMed/NCBI
|
|
22
|
Chen C, Xu N, Jiang X, Wu W, Zhou X, Liu
L, Huang J, Yin C, Cao R, Liao L, et al: Clinical characteristics
of chronic myeloid leukemia with T315I mutation and the efficacy of
ponatinib. Nan Fang Yi Ke Da Xue Xue Bao. 39:364–368. 2019.(In
Chinese). PubMed/NCBI
|
|
23
|
Jabbour E, Kantarjian H, Jones D, Breeden
M, Garcia-Manero G, O'Brien S, Ravandi F, Borthakur G and Cortes J:
Characteristics and outcomes of patients with chronic myeloid
leukemia and T315I mutation following failure of imatinib mesylate
therapy. Blood. 112:53–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nicolini FE, Mauro MJ, Martinelli G, Kim
DW, Soverini S, Müller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH,
et al: Epidemiologic study on survival of chronic myeloid leukemia
and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I
mutation. Blood. 114:5271–5278. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ortiz CA, Alvarez YP, Dongo-Pflucker KL,
Valdivia E, Mendoza Fernández J, Dávila S and Mora-Alférez P:
Mutations in the BCR-ABL1 gene in a peruvian patient with acute
lymphoblastic leukemia resistant to therapy. Rev Fac Cien Med Univ
Nac Cordoba. 74:162–166. 2017.(In Spanish). PubMed/NCBI
|
|
26
|
Takahashi N, Miura M, Kuroki J, Mitani K,
Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, et
al: Multicenter phase II clinical trial of nilotinib for patients
with imatinib-resistant or -intolerant chronic myeloid leukemia
from the East Japan CML study group evaluation of molecular
response and the efficacy and safety of nilotinib. Biomark Res.
2:62014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abulaiti D, Tuerxun N, Wang H, Abulizi P,
Zhao F, Liu Y and Hao J: Differences in variants in the structural
domain of BCR-ABL1 kinase between Chinese Han and Minority patients
with chronic myeloid leukemia by sanger sequencing and
next-generation sequencing. Cytogenet Genome Res. 162:201–206.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim D, Kim DW, Cho BS, Goh HG, Kim SH, Kim
WS, Lee J, Kweon IY, Park SH, Yoon JH, et al: Structural modeling
of V299L and E459K Bcr-Abl mutation, and sequential therapy of
tyrosine kinase inhibitors for the compound mutations. Leuk Res.
33:1260–1265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Zhu M, Li M, Ni D, Wang Y, Deng
L, Du K, Lu S, Shi H and Cai C: Mechanistic insights into
co-administration of allosteric and orthosteric drugs to overcome
drug-resistance in T315I BCR-ABL1. Front Pharmacol. 13:8625042022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Innes AJ, Hayden C, Orovboni V, Claudiani
S, Fernando F, Khan A, Rees D, Byrne J, Gallipoli P, Francis S, et
al: Impact of BCR::ABL1 single nucleotide variants on asciminib
efficacy. Leukemia. 38:2443–2455. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cortes J, Apperley J, Lomaia E, Moiraghi
B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH,
Schiffer CA, et al: Ponatinib dose-ranging study in chronic-phase
chronic myeloid leukemia: A randomized, open-label phase 2 clinical
trial. Blood. 138:2042–2050. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hughes TP, Mauro MJ, Cortes JE, Minami H,
Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, et al:
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor
failure. N Engl J Med. 381:2315–2326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B,
Zhang Y, Meng L, Zhu H, Du X, et al: Olverembatinib (HQP1351), a
well-tolerated and effective tyrosine kinase inhibitor for patients
with T315I-mutated chronic myeloid leukemia: Results of an
open-label, multicenter phase 1/2 trial. J Hematol Oncol.
15:1132022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fisher CL, Randazzo F, Humphries RK and
Brock HW: Characterization of Asxl1, a murine homolog of Additional
sex combs, and analysis of the Asx-like gene family. Gene.
369:109–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Boultwood J, Perry J, Zaman R,
Fernandez-Santamaria C, Littlewood T, Kusec R, Pellagatti A, Wang
L, Clark RE and Wainscoat JS: High-density single nucleotide
polymorphism array analysis and ASXL1 gene mutation screening in
chronic myeloid leukemia during disease progression. Leukemia.
24:1139–1145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Makishima H, Jankowska AM, McDevitt MA,
O'Keefe C, Dujardin S, Cazzolli H, Przychodzen B, Prince C, Nicoll
J, Siddaiah H, et al: CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations
and additional chromosomal aberrations constitute molecular events
in chronic myelogenous leukemia. Blood. 117:e198–e206. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Grossmann V, Kohlmann A, Zenger M,
Schindela S, Eder C, Weissmann S, Schnittger S, Kern W, Müller MC,
Hochhaus A, et al: A deep-sequencing study of chronic myeloid
leukemia patients in blast crisis (BC-CML) detects mutations in
76.9% of cases. Leukemia. 25:557–560. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Valikhani A, Poopak B, Ferdowsi S, Azizi
Tabesh G, Ghaffari SH, Saraf Kazeruoni E, Rezaei N, Farshchi A and
Amirizadeh N: ASXL1 and JAK2V617F gene mutation screening in
Iranian patients with chronic myeloid leukemia. Asia Pac J Clin
Oncol. 13:e41–e47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pratcorona M, Abbas S, Sanders MA,
Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, Zeilemakers A,
Löwenberg B and Valk PJ: Acquired mutations in ASXL1 in acute
myeloid leukemia: Prevalence and prognostic value. Haematologica.
97:388–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chou WC, Huang HH, Hou HA, Chen CY, Tang
JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, et al: Distinct clinical
and biological features of de novo acute myeloid leukemia with
additional sex comb-like 1 (ASXL1) mutations. Blood. 116:4086–4094.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gelsi-Boyer V, Trouplin V, Roquain J,
Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet
C, Zerazhi H, et al: ASXL1 mutation is associated with poor
prognosis and acute transformation in chronic myelomonocytic
leukaemia. Br J Haematol. 151:365–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yonal-Hindilerden I, Daglar-Aday A,
Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS and Sargin D:
Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F
allele burden in Philadelphia-negative myeloproliferative
neoplasms. J Blood Med. 6:157–175. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Thol F, Friesen I, Damm F, Yun H,
Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A,
Wichmann M, et al: Prognostic significance of ASXL1 mutations in
patients with myelodysplastic syndromes. J Clin Oncol.
29:2499–2506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
D'Altri T, Wilhelmson AS, Schuster MB,
Wenzel A, Kalvisa A, Pundhir S, Meldgaard Hansen A and Porse BT:
The ASXL1-G643W variant accelerates the development of CEBPA mutant
acute myeloid leukemia. Haematologica. 106:1000–1007. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bidikian A, Kantarjian H, Jabbour E, Short
NJ, Patel K, Ravandi F, Sasaki K and Issa GC: Prognostic impact of
ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood
Cancer J. 12:1442022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alikian M, Gale RP, Apperley JF and Foroni
L: Molecular techniques for the personalised management of patients
with chronic myeloid leukaemia. Biomol Detect Quantif. 11:4–20.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kohlmann A, Grossmann V, Nadarajah N and
Haferlach T: Next-generation sequencing-feasibility and
practicality in haematology. Br J Haematol. 160:736–753. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Y, Swoboda DM, Grover A, Nodzon L,
Zhang L and Pinilla-Ibarz J: T315I-mutated myeloid sarcoma. Leuk
Res Rep. 12:1001842019.PubMed/NCBI
|
|
49
|
Andorsky D, Kota V and Sweet K: Exploring
treatment decision-making in chronic myeloid leukemia in chronic
phase. Front Oncol. 14:13692462024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu T, Wang C, Fu Y, Yang YP and Tan YH:
Olverembatinib combined with inotuzumab ozogamicin in relapsed
refractory Philadelphia chromosome-positive acute lymphoblastic
leukemia: A case report. Medicine (Baltimore). 103:e389852024.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Senapati J, Sasaki K, Issa GC, Lipton JH,
Radich JP, Jabbour E and Kantarjian HM: Management of chronic
myeloid leukemia in 2023-common ground and common sense. Blood
Cancer J. 13:582023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nicolini FE, Huguet F, Huynh L, Xu C,
Bouvier C, Yocolly A and Etienne G: A multicenter retrospective
chart review study of treatment and disease patterns and clinical
outcomes of patients with chronic-phase chronic myeloid leukemia in
third-line treatment or with T315I mutation. Cancers (Basel).
15:41612023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Amin Muhammad A, Mir Ghazi E, Ali A, Tam
E, Woan K, Chaudhary P, Yaghmour G and Ladha A: Combination therapy
with asciminib and ponatinib as a bridge to brexucabtagene
autoleucel and maintenance in a patient with relapsed refractory
philadelphia positive B-cell acute lymphoblastic leukemia. J Med
Cases. 15:261–266. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F,
Qiu M, Zhou P, Xia Z, Zeng K, et al: The BCL-2 inhibitor APG-2575
resets tumor-associated macrophages toward the M1 phenotype,
promoting a favorable response to anti-PD-1 therapy via NLRP3
activation. Cell Mol Immunol. 21:60–79. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Korfi K, Mandal A, Furney SJ, Wiseman D,
Somervaille TCP and Marais R: A personalised medicine approach for
ponatinib-resistant chronic myeloid leukaemia. Ann Oncol.
26:1180–1187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li Z, Peng D, Deng J, Xiong L, Yin P, Hu
J, Qian C, Yao L, Yin H, Hong M and Wu Q: New ABL1 kinase domain
mutations in BCR::ABL1-positive acute lymphoblastic leukemia.
Cancer Med. 13:e703172024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Choi EJ: Asciminib: The first-in-class
allosteric inhibitor of BCR::ABL1 kinase. Blood Res 58(S1).
S29–S36. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li C, Wang Y, Xu D, Zhang P, Ding X, Zhang
N, Xiao M, Huang L and Meng L: E255K and G250E mutation appearing
in a patient with e19a2 chronic myeloid leukemia resistant to
imatinib. Clin Lab. 61:183–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
